Analyzing Cost of Revenue: Merck & Co., Inc. and Celldex Therapeutics, Inc.

Analyzing Cost of Revenue: Merck & Co., Inc. vs. Celldex Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. This analysis compares Merck & Co., Inc., a global leader, with Celldex Therapeutics, Inc., a smaller biotech firm, from 2014 to 2023.

Key Insights

Merck's cost of revenue consistently dwarfs that of Celldex, reflecting its expansive operations. In 2022, Merck's cost of revenue peaked at approximately $17.4 billion, a 37% increase from 2014. In contrast, Celldex's highest cost was in 2016, at around $102 million, before plummeting to just $1.4 million in 2022.

Trends Over Time

Merck's cost of revenue shows a steady upward trend, indicative of its growth and market expansion. Meanwhile, Celldex's fluctuating costs highlight the volatility and challenges faced by smaller biotech companies. This comparison underscores the diverse financial landscapes within the pharmaceutical sector.